Specialties Breast Cancer
ClinicalInterests He has been engaged in multidisciplinary comprehensive treatment forbreast cancer, and has been researching on breast cancer adjuvant chemotherapy,endocrine therapy and biological targeting therapy.
Experience
He presidedover a number of National Natural Science Foundation and provincial researchprojects
Education
2014-2017: Medical Doctor, Sun Yat-senUniversity, Guangzhou, Guangdong, China
2011-2014: Master of Medicine, SunYat-sen University, Guangzhou, Guangdong, China
2006-2011: Bachelor of Medicine, XiangYaschool of medicine, Central South University, Changsha, Hunan, China
Awards andHonors
(1) Nationalscholarship for Postgraduates, 2016,China.
(2) National Ministry of Health-DaiichiSankyo Corporation scholarship, 2015,China
(3) The silver medal winner of the third national general surgery essaycompetition Guangdong Province finals
(4)The member of editorial board of Chinese Journal of General Surgery
Professionalmemberships
Member of HealthManagement Committee of Guangdong of Primary Medicine
Publications
① JiF#,Yang CQ#,Li XL#,Zhang LL, Yang M, Li JQ, Gao HF, Zhu T, Cheng MY, LiWP, Wu SY, Zhong AL, Wang K*.Risk of breast cancer-related death in women witha prior cancer. Aging (Albany NY). 2020;12(7):5894-5906.
② LiWP#, GaoHF#, JiF#, ZhuT, Cheng MY, Yang M, Yang CQ, Zhang LL, Li JQ, ZhangJS, Wang K*.The role of adjuvant chemotherapy in stage I-III male breast cancer:a SEER-based analysis. Ther Adv Med Oncol. 2020;12:1758835920958358.
③ JiF#, ZhangY#, ZhuZB#, GuoY, Shen SL, Cao QH, Li SQ, Peng BG, Liang LJ, HuaYP*. Lowlevels of gp96 indicate a worse prognosis in early-stage HCC patients afterhepatectomy. Hum Pathol. 2019;86:193-202
④ JiF#,Xiao WK#,Yang CQ#,Yang M, Zhang LL, Gao HF, Lin YF, Zhu T, Cheng MY,Li WP, Pan WJ, Zhuang XS, Wang K*.Tumor location of the central and nipple portionis associated with impaired survival for women with breast cancer. Cancer Manag Res. 2019;11:2915-2925
⑤ JiF#,Zhang ZH#,Zhang Y#,Shen SL, Cao QH, Zhang LJ, Li SQ, Peng BG, Liang LJ,Hua YP*.Low expression of c-Myc protein predicts poor outcomes in patients withhepatocellular carcinoma after resection. BMC Cancer. 2018;18:460.
⑥ JiF#,Liang Y#,Fu S#,Chen D, Cai X, Li S, Peng B, Liang L, Hua Y*.Prognostic Value of Combined PreoperativePrognostic Nutritional Index and Body Mass Index inHCC after Hepatectomy. HPB (Oxford). 2017;19(8):695-705
⑦ JiF#, FuSJ#,Shen SL#,Zhang LJ, Cao QH, Li SQ, Peng BG, Liang LJ, Hua YP*.Theprognostic value of combined TGF-β1 and ELF in hepatocellular carcinoma. BMCCancer.2015;15:116
⑧ JiF#,Liang Y#,Fu SJ#,Guo ZY, Shu M, Shen SL, Li SQ, Peng BG, Liang LJ, HuaYP*. Anovel and accurate predictor of surviveal for patients with hepatocellular carcinomaafter surgical resection: the neutrophil to lymphocyte ratio (NLR) combinedwith the aspartate aminotransferase/platelet count ratio index (APRI). BMC Cancer.2016;16:137.
⑨ HeXS#*, Ji F#, Zhang ZH#,Tang Y, Yang L, Huang S, Li W, Su Q, Xiong W, Zhu Z, Wang L, Lv L, Yao J, Zhang L, Zhang L, Guo Z*. Combined Liver-kidney PerfusionEnhances Protective Effects of Normothermic Perfusion on Livers Grafts from Donation after Cardiac Death. Liver Transpl. 2018;24(1):67-79
